Our Programs

Pipeline

We are leveraging our deep understanding of recent biological discoveries in endocrinology to build a strong clinical pipeline. Our focus is on advancing the development of novel, potentially first-in-class treatments for endocrine diseases with significant unmet need. Livoletide (AZP-531) is an unacylated ghrelin analogue for treatment of Prader-Willi Syndrome and nevanimibe (ATR-101) is an ACAT1 inhibitor currently being investigated in two orphan adrenal indications, Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).

Millendo Pipeline